Together with National Hispanic Energy Council, Avangrid brings together 15 Hispanic legislators, municipal officials, business executives, and nonprofit leaders to discuss energy issues facing Hispanic community; commits to convening annually Avangrid to become a Business Member of the National Hispanic Caucus of State Legislators, and Avangrid CEO Pedro Azagra to become member of the Board of Trustees of the National Hispanic Energy Council Photos from the event available HERE Today, Avangrid, Inc. (NYSE:AGR), a leading sustainable energy company and member of the Iberdrola Group, convened Connecticut's first-ever energy-related Hispanic Roundtable. With more than 15 Hispanic leader

NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Fly-E Group, Inc. (NASDAQ:FLYE) ("Fly-E" or the "Company"), an electric vehicle company engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories, today announced its unaudited financial results for the second quarter and first half of fiscal year 2025 ended September 30, 2024. Selected Second Quarter Financial Results Revenue: $6.8 million, compared with $8.8 million in Q2 2023.Gross profit: $2.9 million, compared with $3.8 million in Q2 2023.Total operating expense: $4.1 million, compared with $2.7 million in Q2 2023.Net loss: $1.1 million, or $0.05 per share, compared with ne

Virtus Total Return Fund Inc. (NYSE:ZTR) today announced the following monthly distributions: Amount of Distribution Ex-Date/Record Date Payable Date $0.05 December 12, 2024 December 30, 2024 $0.05 January 13, 2025 January 30, 2025 $0.05 February 13, 2025 February 27, 2025 $0.05 March 13, 2025 March 28, 2025 The Fund previously announced the following monthly distribution on August 29, 2024: Amount of Distribution Ex-Date Record Date Payable Date $0.05 November 12, 2024 November 12, 2024 November 27, 2024 Under the terms of its Managed

SANTA BARBARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- AppFolio, Inc. (NASDAQ:APPF), the technology leader powering the future of the real estate industry, announced Reedy & Company, a leading Memphis-based property management company has signed a five-year contract and is fully integrated with AppFolio's suite of products to support its entire portfolio. Reedy & Company manages a diverse portfolio of more than 3,500 properties including multi-family, single-family, affordable housing and commercial units across Tennessee, Mississippi and Arkansas. After identifying the need for a robust, scalable solution to support its growing real estate portfolio and evaluating a number of leading

Cantor Fitzgerald upgraded Aclaris Therapeutics from Neutral to Overweight

HSBC Securities downgraded Target from Buy to Hold and set a new price target of $138.00

Macquarie downgraded NIO from Outperform to Neutral and set a new price target of $4.80 from $6.60 previously

UBS upgraded Logitech Int'l SA from Sell to Neutral

4 - RE/MAX Holdings, Inc. (0001581091) (Issuer)

4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

4 - PIONEER MUNICIPAL HIGH INCOME FUND, INC. (0001223026) (Issuer)

4 - PIMCO MUNICIPAL INCOME FUND (0001140392) (Issuer)

4 - Ovintiv Inc. (0001792580) (Issuer)

4 - TETRA TECH INC (0000831641) (Issuer)

4 - RE/MAX Holdings, Inc. (0001581091) (Issuer)

4 - AZEK Co Inc. (0001782754) (Issuer)

F-3/A - DAVIS COMMODITIES Ltd (0001949478) (Filer)

DEF 14A - SRM Entertainment, Inc. (0001956744) (Filer)

DEFR14A - Pearl Holdings Acquisition Corp (0001856161) (Filer)

8-K - EAST WEST BANCORP INC (0001069157) (Filer)

Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity

Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling

For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring effective at the end of 2024. He will continue to serve as a strategic advisor and consultant while the Company seeks a new Head of R&D. "Sam's passion for pediatric oncology

Former UPS executive strengthens depth of business expertise Assurant, Inc. (NYSE:AIZ), a leading global business services company that supports, protects, and connects major consumer purchases, today announced the appointment of Kevin Warren, former chief marketing and customer experience officer at UPS, to its Board of Directors, effective January 15, 2025. Warren will serve on the company's Compensation and Talent committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241120134273/en/Kevin M. Warren (Photo: Business Wire) "We are pleased to welcome Kevin to our Board," said Assurant Board of Directors Chair, Elaine Rosen

THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth investing platform within global asset manager TPG – since September 2023. "I am honored to join the Lexicon Board of Directors at this pivotal moment in the company's history, and to support its mis

NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as t

FALLS CHURCH, Va., Nov. 20, 2024 (GLOBE NEWSWIRE) -- The board of directors of Northrop Grumman Corporation (NYSE:NOC) declared a quarterly dividend of $2.06 per share on Northrop Grumman common stock, payable December 18, 2024, to shareholders of record as of the close of business December 2, 2024. Northrop Grumman is a leading global aerospace and defense technology company. Our pioneering solutions equip our customers with the capabilities they need to connect and protect the world, and push the boundaries of human exploration across the universe. Driven by a shared purpose to solve our customers' toughest problems, our employees define possible every day. Contact: [email protected]

UBS AG announced today that it will redeem all of the outstanding securities in each of the seven series of UBS-issued exchange traded notes set forth in the following table (collectively, the "ETNs"). UBS AG expects to deliver redemption notices with respect to each of the ETNs to holders of the applicable ETNs with Call Settlement Dates as set forth in the table below. Table-1 ETN Ticker ETN Name and Prospectus Supplement [1] CUSIP Call Settlement Date DJCB ETRACS Bloomberg Commodity Index Total ReturnSM ETN Series B due October 31, 2039[2] 90269A450 12/12/2024 WUCT ETRACS Whitney US Critical Technologies ETN due March 13, 20

LAS VEGAS, Nov. 20, 2024 /PRNewswire/ -- The Board of Directors for Southwest Gas Holdings, Inc. ("Southwest Gas") (NYSE: SWX) has declared the following first quarter cash dividend: Common Stock Payable                          March 3, 2025 Of Record                        February 18, 2025 Dividend                          $0.62 per share The dividend equates to $2.48 per share on an annualized basis.  The Company has paid quarterly dividends continuously since going public in 1956. Additional dividend information, including the tax status of Southwest Gas' dividend distributions, can be obtained through the Investor Relations section of Southwest Gas' website, www.swgasholdings.com. Abou

PANAMA CITY, Panama, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Copa Holdings, S.A. (NYSE:CPA), today announced financial results for the third quarter of 2024 (3Q24). The terms "Copa Holdings" and the "Company" refer to the consolidated entity. The following financial information, unless otherwise indicated, is presented in accordance with International Financial Reporting Standards (IFRS). See the accompanying reconciliation of non-IFRS financial information to IFRS financial information included in the financial tables section of this earnings release. Unless otherwise stated, all comparisons with prior periods refer to the third quarter of 2023 (3Q23). OPERATING AND FINANCIAL HIGHLIGHTS Copa

SC 13G - OptiNose, Inc. (0001494650) (Subject)

SC 13D/A - Intuitive Machines, Inc. (0001844452) (Subject)

SC 13D - AMERICAN SHARED HOSPITAL SERVICES (0000744825) (Subject)

SC 13G - Globavend Holdings Ltd (0001978527) (Subject)

Macquarie analyst Chad Beynon maintains Monarch Casino & Resort (NASDAQ:MCRI) with a Neutral and maintains $76 price target.

To gain an edge, this is what you need to know today. GDP Brings Buying  Please click here for an enlarged chart of Invesco QQQ Trust Series 1 (NASDAQ:QQQ). Note the following: The chart shows a drop in QQQ.  The drop in QQQ was triggered by speculative sentiment pulling back.  As a reader of The Arora Report, you knew in advance that speculative sentiment could fall as a result of Tesla Inc (NASDAQ:TSLA) earnings. The chart shows that QQQ is approaching the support zone. RSI on the chart shows that QQQ is now oversold.  Oversold markets tend to bounce. The chart shows that the volume was low on the selloff.  This indicates a lack of conviction in selling. Especially hard hit in

Macquarie analyst Chad Beynon maintains Las Vegas Sands (NYSE:LVS) with a Outperform and lowers the price target from $58 to $56.

RBC Capital analyst Sam Crittenden maintains TECK RESOURCES LIMITED (TSX:TECK) with a Outperform and lowers the price target from C$91 to C$88.

Recently, on July 4, 2024, a significant insider purchase was recorded at Allied Gaming & Entertainment Inc. as Large owner Choi Roy bought $456,750 worth of shares (360,000 units at $1.27), increasing direct ownership by 14% to 2,871,822 units (SEC Form 4). This purchase is notable for the size of the transaction and the percentage increase in direct ownership, indicating a strong belief in the company's future prospects. Insider purchases are generally viewed positively by investors as they signal confidence from those with intimate knowledge of the company's operations. Examining other recent insider transactions at Allied Gaming & Entertainment Inc., we notice a few patterns worth explo

Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan